InMed Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

INM$15.56+17.8%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Shareholders’ Equity

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY UNAUDITED

For the Three Months ended September 30, 2024 and 2023

Common Shares · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total
	#	$	$	$	$	$
Balance July 1, 2024	445,948	82,784,400	35,368,899	(109,075,759)	128,569	9,206,109
Private placement	186,364	1,030,063	-	-	-	1,030,063
Share issuance costs	-	(191,824)	-	-	-	(191,824)
Exercise of pre-funded warrants	34,701	576,034	(576,034)	-	-	-
Loss for the period	-	-	-	(1,677,868)	-	(1,677,868)
Share-based compensation	-	-	28,964	-	-	28,964
Balance September 30, 2024	667,013	84,198,673	34,821,829	(110,753,627)	128,569	8,395,444

Common Shares · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total
	#	$	$	$	$	$
Balance July 1, 2023	166,410	77,620,252	35,741,115	(101,400,209)	128,569	12,089,727
Net loss	-	-	-	(2,536,828)	-	(2,536,828)
Share-based compensation	-	-	25,191	-	-	25,191
Balance September 30, 2023	166,410	77,620,252	35,766,306	(103,937,037)	128,569	(9,578,090)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.